Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central
nervous system afflicting nearly three million individuals worldwide. Neuroimmune …

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By map** 55 neoantigen …

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the
clinical care of patients with cancer. However, whether the T cell response to checkpoint …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …

Neoantigens play a key role in the recognition of tumour cells by T cells; however, only a
small proportion of neoantigens truly elicit T-cell responses, and few clues exist as to which …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …